Physiology and Therapeutics of Vascular Endothelial Growth Factor in Tumor Immunosuppression

Title: Physiology and Therapeutics of Vascular Endothelial Growth Factor in Tumor Immunosuppression

Volume: 9 Issue: 6

Author(s): Benjamin Johnson, Takuya Osada, Timothy Clay, Herbert Lyerly and Michael Morse

Affiliation:

Abstract: Vascular endothelial growth factor (VEGF), known as a primary mediator of tumor-induced angiogenesis, is now understood to have a role in tumor-associated immunosuppression. Initially, VEGF was identified to alter the growth and maturation of the immature granulocyte-macrophage progenitors, and more recently it has been noted that it prevents dendritic cell (DC) precursors from developing into mature, antigenpresenting DC. VEGF is associated with recruitment of macrophages to the tumor stroma and VEGF inhibition of myeloid progenitor maturation is associated with the development tumor associated macrophages (TAM) which possess immunosuppressive capacity as well. Therapies intended to inhibit VEGF or VEGF receptors have demonstrated improved anti-tumor immunity and enhanced responses to cancer vaccines.

Cite this article as:

Johnson Benjamin, Osada Takuya, Clay Timothy, Lyerly Herbert and Morse Michael, Physiology and Therapeutics of Vascular Endothelial Growth Factor in Tumor Immunosuppression, Current Molecular Medicine 2009; 9 (6) . https://dx.doi.org/10.2174/156652409788970634